abiraterone,olaparib
astrazeneca,merck
['olaparib']
 thx for the post but i'm not sure about your phrasing... there is no relevant benefit in hrr neg, while you get years of added clinical and financial tox. in hrr+, there is a trend towards os benefit, but at great cost... would giving olaparib at progression do the same?
Enjoying oncology, without meaning to sound too cynical